Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 125,990

Document Document Title
WO/2017/050171A1
Provided are crystal forms I, II, III and IV of a pyrroloquinoline quinone sodium salt and a preparation method thereof. Also provided are a pharmaceutical composition, a cosmetic composition, a functional food or a nutritional agent con...  
WO/2017/051303A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1, R2, R3, R4 and X are...  
WO/2017/050807A1
The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl- bound N-amide moiety derived from an α-amino acid of formula I where the variables are as defined in the claims and the description. The invention furthe...  
WO/2017/051276A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined...  
WO/2017/051188A1
Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the metho...  
WO/2017/053346A1
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously a...  
WO/2017/053773A1
The invention described herein relates to novel personalized methods for treating, reducing or reversing cognitive decline utilizing a number of cognitive biological functions (factors), including metabolic parameters.  
WO/2017/050978A1
The present invention relates to 2,3,4,5-tetrahydropyridin-6-amine compound inhibitors of beta-secretase having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The invention is also directed t...  
WO/2017/049470A1
The present application discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.  
WO/2017/052394A1
Novel imidazo[4,5-c]pyridine and imidazo[4,5-b]pyridine derivatives of formula (I) as antagonists of 5-HT6 receptors, particularly for use in the prevention or treatment of schizophrenia, anxiety, depression, maniac depression, epilepsy,...  
WO/2017/049069A1
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.  
WO/2017/049001A1
A method of treating dry eye disease is provided. The method includes administering to a patient in need thereof an effective amount of a pharmaceutical composition that includes an isolated clusterin or an isolated protein substantially...  
WO/2017/046172A1
The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the g...  
WO/2017/048778A1
Disclosed here is a method of transporting a therapeutic or diagnostic agent across a blood-brain barrier or a blood-cochlear barrier or a blood-cerebrospinal fluid barrier of a subject, comprising administering to a subject an amount of...  
WO/2017/048159A1
The invention relates to novel N,N-substituted 3,7-diazabicyclo[3.3.1]nonanes which exhibit the characteristics of positive modulators of AMPA-receptor activity and which may be used in the prevention and treatment of diseases of the ner...  
WO/2017/047769A1
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selec...  
WO/2017/047777A1
Provided is a serotonin deficiency amelioration agent for after stress-load release, that improves serotonin deficiencies after a stress load has been released. The serotonin deficiency amelioration agent for after stress-load release ha...  
WO/2017/049252A1
The present invention generally provides vectors, compositions, and methods of using the same for treating neurological disorders, including managing pain. The compositions and methods include the use of G protein-coupled receptors and l...  
WO/2017/046117A1
Compounds of formula (I) (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modu...  
WO/2017/048808A1
The present disclosure provides variant light-responsive polypeptides, and nucleic acids comprising nucleotide sequences encoding the light-responsive polypeptides. The present disclosure provides methods, devices, and systems for contro...  
WO/2017/046794A1
Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said proces...  
WO/2017/046737A1
The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. T...  
WO/2017/049192A1
The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1- inactivation-associated disorder (e.g., fragile X syndrome).  
WO/2017/047776A1
Provided is a blood tryptophan concentration elevation inhibitor. The blood tryptophan concentration elevation inhibitor has, as an effective component thereof, lactic acid bacterium of the genus Lactobacillus, a processed product thereo...  
WO/2017/046675A1
The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined ...  
WO/2017/046739A1
The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds o...  
WO/2017/046738A1
The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the...  
WO/2017/045599A1
Provided are a cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, and the preparation and use thereof. The cyclohexane derivative has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower a...  
WO/2017/045053A1
The present invention describes an oral pharmaceutical composition containing cannabinoid(s), an oily liquid solvent and a co-solvent, and a method for preparing and using same for the treatment of neurological disorders, especially refr...  
WO/2017/048720A1
Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.  
WO/2017/042274A1
The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for...  
WO/2017/044551A1
Provided herein are methods for increasing PPARalpha activity and methods for treating PPARalpha related diseases (e.g., mitochondrial diseases).  
WO/2017/044567A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: (I). The compounds induce FOXO1 transcription factor translocation to the nucleus by modulatin...  
WO/2017/044693A1
A combination of a muscarinic cholinergic receptor agonist with a non-anticholinergic antiemetic agent, and the optional addition of an acetyl choline esterase inhibitor, for the treatment of hypocholinergic disorder of the central nervo...  
WO/2017/044491A1
This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as faso...  
WO/2017/044807A3
The invention provides for methods for treating Alzheimer's Disease in a subject by reducing ER-MAM localized APP-C99.  
WO/2017/042196A3
The present invention relates to agents that prevent or reverse process of stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of stem senescence.  
WO/2017/044486A1
Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precu...  
WO/2017/042114A1
The present invention relates to compounds of formula (I); hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted b...  
WO/2017/044714A1
A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.  
WO/2017/041180A1
Compounds having the Formula (I), and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (Formula I)) are useful as kinase inhibitors or modulators, including BTK modulation or inhibiti...  
WO/2017/042314A1
The present invention relates to methods and pharmaceutical composition for the treatment of post-traumatic epilepsies. In particular, the present invention relates to a method of treating post-traumatic epilepsy (PTE) in a subject in ne...  
WO/2017/042267A1
The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.  
WO/2017/043494A1
The purpose of the present invention is to provide a microcapsule, said microcapsule containing a biodegradable polymer and risperidone and having excellent sustained release properties, and a method for manufacturing the same. A microca...  
WO/2017/044571A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...  
WO/2017/044497A1
Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein t...  
WO/2017/044516A1
The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined ...  
WO/2017/043636A1
To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urinatio...  
WO/2017/044503A1
Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein t...  
WO/2017/041733A1
Provided is a polypeptide that inhibits Aβ protein aggregation of Alzheimer's disease, and an amino acid sequence thereof is Xaa1-Xaa2-Xaa3-Xaa4. Xaa1 and Xaa3 are identical amino acids and selected from I, V or L, Xaa2 is selected from...  

Matches 651 - 700 out of 125,990